TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27744512

Group type: EXPERIMENTAL
Intervention: Patient ratings of health-related quality of life (HRQOL) using SF-36 and EORTC QLQ-BN20.
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Cognitively impaired subgroup ratings.
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Cognitively intact subgroup ratings.
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Bland-Altman plots for patient-proxy agreement.
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Concordance correlation coefficient (CCC) for HRQOL domains.
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Percentage of perfect agreement (PD ±0).
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Mean difference between patients and proxies in cognitively impaired patients.
Number of subjects: 246
Study: 27745744

Group type: EXPERIMENTAL
Intervention: Olaparib plus itraconazole
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Olaparib plus rifampin
Number of subjects: 81

Group type: COMPARATOR
Intervention: Olaparib alone
Number of subjects: 81
Study: 27746093

Group type: EXPERIMENTAL
Intervention: Cytokine response score derived from signaling conditions
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Baseline levels of phosphorylated STAT (pSTAT) proteins
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Response capacity of naive versus memory T cell subsets to IL-6, IFN-α, IL-21, and IFN-γ
Number of subjects: 91
Study: 27746690

Group type: EXPERIMENTAL
Intervention: Red Ginseng (RG) supplementation for 2 weeks
Number of subjects: 14
Study: 27747277

Group type: EXPERIMENTAL
Intervention: Single clips
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multi-firing clip device
Number of subjects: 0
Study: 27747511

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) dose 6-<8 mg/week in biologic-naïve patients
Number of subjects: 5494

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) dose in biologic-exposed patients
Number of subjects: 5494

Group type: EXPERIMENTAL
Intervention: Increased MTX doses
Number of subjects: 5494
Study: 27747515

Group type: EXPERIMENTAL
Intervention: TCZ 4 mg/kg
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: TCZ 8 mg/kg
Number of subjects: 213
Study: 27747583

Group type: EXPERIMENTAL
Intervention: 40 mg/0.4 mL adalimumab
Number of subjects: 125

Group type: COMPARATOR
Intervention: 40 mg/0.8 mL adalimumab
Number of subjects: 125
Study: 27747585

Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (TCZ-SC) 162 mg weekly or every other week for up to 84 weeks
Number of subjects: 217
Study: 27748218

Group type: EXPERIMENTAL
Intervention: Potential smoking-related conditions (total 120 patients)
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Cardiovascular disease (18 patients)
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Neoplasm (6 patients)
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Respiratory disease (67 patients)
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Dental disease (9 patients)
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Postoperative complication (7 patients)
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Peptic ulcer disease (9 patients)
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Other conditions (eye condition, bony condition)
Number of subjects: 893
Study: 27748745

Group type: EXPERIMENTAL
Intervention: METRNL overexpression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental downregulation of METRNL
Number of subjects: 0

Group type: COMPARATOR
Intervention: METRNL expression in adipocytes of obese children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Withdrawal of PPARγ agonist rosiglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: METRNL expression in SVF cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: METRNL expression
Number of subjects: 0
Study: 27749456

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg every 3 weeks with 4 to 8 cycles of paclitaxel plus carboplatin, continued until progression or for up to 24 months.
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg for more than 15 months.
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Bevacizumab therapy beyond 15 months.
Number of subjects: 1021
Study: 27749650

Group type: EXPERIMENTAL
Intervention: Immune activation marker %CD8+CD38+DR+
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: E-selectin, a marker of endothelial inflammation
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Coronary plaque
Number of subjects: 31
Study: 27749683

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Optimism
Number of subjects: 164
Study: 27750483

Group type: EXPERIMENTAL
Intervention: AT7519M (27 mg/m)
Number of subjects: 0
Study: 27751676

Group type: EXPERIMENTAL
Intervention: Selumetinib, 75-mg single dose
Number of subjects: 6
Study: 27751772

Group type: EXPERIMENTAL
Intervention: International travel to southern Asia
Number of subjects: 2001

Group type: EXPERIMENTAL
Intervention: Antibiotic use during travel
Number of subjects: 2001

Group type: EXPERIMENTAL
Intervention: Traveller's diarrhoea that persisted after return
Number of subjects: 2001

Group type: EXPERIMENTAL
Intervention: Pre-existing chronic bowel disease
Number of subjects: 2001

Group type: EXPERIMENTAL
Intervention: Post-travel colonisation
Number of subjects: 2001

Group type: EXPERIMENTAL
Intervention: Sustained colonisation at 12 months
Number of subjects: 2001

Group type: EXPERIMENTAL
Intervention: CTX-M enzyme group 9 ESBLs
Number of subjects: 2001

Group type: EXPERIMENTAL
Intervention: Onward transmission to household members
Number of subjects: 2001

Group type: EXPERIMENTAL
Intervention: Probability of transmitting ESBL-E to another household member
Number of subjects: 2001
Study: 27751847

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg orally once daily
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 210
Study: 27751941

Group type: EXPERIMENTAL
Intervention: Global fMRI signal analysis
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: fMRI data preparation techniques
Number of subjects: 1000
Study: 27752238

Group type: EXPERIMENTAL
Intervention: Multilayer compression bandages (2 layers)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Crepe bandages
Number of subjects: 216
Study: 27752357

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg two times per day
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg two times per day
Number of subjects: 956

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 956
Study: 27752787

Group type: EXPERIMENTAL
Intervention: Preoperative mFOLFOX6 therapy (6 cycles)
Number of subjects: 30
Study: 27754946

Group type: EXPERIMENTAL
Intervention: Long episodes of AT/AF
Number of subjects: 5379

Group type: EXPERIMENTAL
Intervention: Short episodes of AT/AF
Number of subjects: 5379

Group type: COMPARATOR
Intervention: No documented AT/AF
Number of subjects: 5379
Study: 27755109

Group type: EXPERIMENTAL
Intervention: Sorafenib treatment
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 302
Study: 27755463

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (RV5)
Number of subjects: 0
Study: 27756076

Group type: EXPERIMENTAL
Intervention: Laser Speckle Flowgraphy (LSFG)
Number of subjects: 20
Study: 27756258

Group type: EXPERIMENTAL
Intervention: OXY111A (myo-inositoltrispyrophosphate)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard cytotoxic treatment
Number of subjects: 69
Study: 27756308

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TS) prophylaxis, daily from 6 weeks of age until exclusion of HIV-infection after cessation of breastfeeding.
Number of subjects: 361
Study: 27756346

Group type: EXPERIMENTAL
Intervention: Tailored family-based intervention for improving lifestyle habits
Number of subjects: 0
Study: 27756385

Group type: EXPERIMENTAL
Intervention: High dietary glycemic index (GI)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Lowest dietary glycemic index (GI)
Number of subjects: 300
Study: 27756403

Group type: EXPERIMENTAL
Intervention: FACIT-F scale (raw score, range 0-52)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: FACIT-F-trans value (range 0-100)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Vitality domain (VT) of the 36-item Short-Form Health Survey (SF-36)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: FACIT-F and VT comparison
Number of subjects: 56
Study: 27756498

Group type: EXPERIMENTAL
Intervention: HMGB1 levels at study entry
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: HMGB1 levels at 10 years
Number of subjects: 131
Study: 27756552

Group type: EXPERIMENTAL
Intervention: Temporary extracorporeal perfusion for 147 ± 52 minutes (range 77-237 minutes)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional reconstruction with radial forearm flaps, N=30
Number of subjects: 8
Study: 27756611

Group type: EXPERIMENTAL
Intervention: Redo POEM
Number of subjects: 46
Study: 27757240

Group type: EXPERIMENTAL
Intervention: Neuromuscular warm-up program (15-min, three times per week for eleven weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Regular warm-up (control group)
Number of subjects: 41
Study: 27757396

Group type: EXPERIMENTAL
Intervention: Transanal endoscopic total mesorectal excision (TME) with the assistance of single port laparoscopic surgery
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transanal endoscopic total mesorectal excision (TME)
Number of subjects: 12
Study: 27757516

Group type: EXPERIMENTAL
Intervention: Higher PEEP
Number of subjects: 2377

Group type: EXPERIMENTAL
Intervention: Lower peak inspiratory pressure
Number of subjects: 2377

Group type: EXPERIMENTAL
Intervention: Lower plateau pressure
Number of subjects: 2377

Group type: EXPERIMENTAL
Intervention: Lower driving pressures
Number of subjects: 2377

Group type: EXPERIMENTAL
Intervention: Lower respiratory rate
Number of subjects: 2377

Group type: COMPARATOR
Intervention: Lower PEEP
Number of subjects: 2377

Group type: COMPARATOR
Intervention: Higher peak inspiratory pressure
Number of subjects: 2377

Group type: COMPARATOR
Intervention: Higher plateau pressure
Number of subjects: 2377

Group type: COMPARATOR
Intervention: Higher driving pressures
Number of subjects: 2377

Group type: COMPARATOR
Intervention: Increased respiratory rate
Number of subjects: 2377

Group type: COMPARATOR
Intervention: Fewer ICU beds
Number of subjects: 2377

Group type: COMPARATOR
Intervention: Older age
Number of subjects: 2377

Group type: COMPARATOR
Intervention: Active neoplasm
Number of subjects: 2377

Group type: COMPARATOR
Intervention: Hematologic neoplasm
Number of subjects: 2377

Group type: COMPARATOR
Intervention: Chronic liver failure
Number of subjects: 2377

Group type: COMPARATOR
Intervention: Lower pH
Number of subjects: 2377

Group type: COMPARATOR
Intervention: Lower PaO2
Number of subjects: 2377
Study: 27757709

Group type: EXPERIMENTAL
Intervention: Endothelin receptor antagonists
Number of subjects: 15

Group type: COMPARATOR
Intervention: No endothelin receptor antagonists
Number of subjects: 15
Study: 27760222

Group type: EXPERIMENTAL
Intervention: Calf raise exercise in patients with peripheral vascular disease
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Calf raise exercise in healthy older adults
Number of subjects: 22
Study: 27760437

Group type: EXPERIMENTAL
Intervention: Novel hemostatic powder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27760529

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 42
Study: 27760543

Group type: EXPERIMENTAL
Intervention: Infants with PSBI
Number of subjects: 37379

Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 37379

Group type: EXPERIMENTAL
Intervention: Parity > 2
Number of subjects: 37379

Group type: EXPERIMENTAL
Intervention: Late antenatal care
Number of subjects: 37379

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids
Number of subjects: 37379

Group type: EXPERIMENTAL
Intervention: Low birth weight
Number of subjects: 37379
Study: 27760758

Group type: EXPERIMENTAL
Intervention: Blocking erythropoietin (EPO)-EPO receptor (R) signaling
Number of subjects: 0
Study: 27760761

Group type: EXPERIMENTAL
Intervention: Triplex vaccine (MVA encoding CMV antigens)
Number of subjects: 24
Study: 27761518

Group type: EXPERIMENTAL
Intervention: mHealth intervention (self-monitoring via daily text messages, wireless devices for weight and steps tracking, 4 motivational interviewing-based phone sessions)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 10
Study: 27762283

Group type: EXPERIMENTAL
Intervention: Roche High Pure TaqMan HCV 2.0 test (HPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abbott RealTime HCV RNA test (ART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCV RNA cutoff of 6 million IU/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timing of sample collection
Number of subjects: 0
Study: 27763941

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRI) treatment with citalopram
Number of subjects: 2280
Study: 27764091

Group type: EXPERIMENTAL
Intervention: Natural pomegranate juice (POMj)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 9
Study: 27764157

Group type: EXPERIMENTAL
Intervention: BM-MNC Early group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BM-MNC Late group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline myocardial viability
Number of subjects: 0
Study: 27764686

Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg every 2 weeks via intravenous infusion) with concurrent palliative RT
Number of subjects: 10
Study: 27764800

Group type: EXPERIMENTAL
Intervention: FGFR2 locus variants (rs3135718)
Number of subjects: 9365

Group type: EXPERIMENTAL
Intervention: FGFR2 locus variants (rs3135724)
Number of subjects: 9365
Study: 27765666

Group type: EXPERIMENTAL
Intervention: elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide regimen
Number of subjects: 50
Study: 27765757

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus ramucirumab (8 mg/kg)
Number of subjects: 168

Group type: COMPARATOR
Intervention: mFOLFOX6 plus placebo
Number of subjects: 168
Study: 27765906

Group type: EXPERIMENTAL
Intervention: Targeted therapy proposed to patients (clinical trial or registered drugs)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Targeted treatment received
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Successful xenografting
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Genomic-driven treatment implementation
Number of subjects: 34
Study: 27766064

Group type: EXPERIMENTAL
Intervention: Taiwanese PNH patients
Number of subjects: 63
Study: 27766119

Group type: EXPERIMENTAL
Intervention: Trial medication (levothyroxine) for 24 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual TSH arm
Number of subjects: 48

Group type: COMPARATOR
Intervention: Higher TSH arm
Number of subjects: 48

Group type: COMPARATOR
Intervention: Home visits
Number of subjects: 48

Group type: COMPARATOR
Intervention: Research Facility visits
Number of subjects: 48
Study: 27766602

Group type: EXPERIMENTAL
Intervention: Gene-Eden-VIR/Novirin (1-4 capsules per day for 2-48 months)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Baseline control group
Number of subjects: 137

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 137

Group type: COMPARATOR
Intervention: Dose-response control group
Number of subjects: 137
Study: 27767222

Group type: EXPERIMENTAL
Intervention: Periodontal therapy (mechanical debridement plus 1 week of amoxicillin/metronidazole)
Number of subjects: 141
Study: 27767943

Group type: EXPERIMENTAL
Intervention: Equine-assisted occupational therapy intervention
Number of subjects: 7

Group type: COMPARATOR
Intervention: Conventional treatments (control group not explicitly mentioned)
Number of subjects: 7
Study: 27768852

Group type: EXPERIMENTAL
Intervention: Neighborhood socioeconomic variables (poverty rate, percentage of single-female-headed households)
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: African American race
Number of subjects: 774

Group type: COMPARATOR
Intervention: Controlling for poverty rate or percentage of single-female-headed households
Number of subjects: 774
Study: 27768855

Group type: EXPERIMENTAL
Intervention: Coastal region
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Urban region
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Mountainous region
Number of subjects: 299

Group type: COMPARATOR
Intervention: Overall assessment
Number of subjects: 299
Study: 27768923

Group type: EXPERIMENTAL
Intervention: Triplet hepatic artery infusion (HAI) and intravenous cetuximab (500 mg/m² cetuximab, 180 mg/m² irinotecan)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Triplet hepatic artery infusion (HAI) and intravenous cetuximab
Number of subjects: 64
Study: 27769214

Group type: EXPERIMENTAL
Intervention: Biomarker panel combined with mp-MRI and VERDICT MRI
Number of subjects: 365

Group type: COMPARATOR
Intervention: mp-MRI
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: VERDICT MRI
Number of subjects: 365
Study: 27770592

Group type: EXPERIMENTAL
Intervention: High-molecular-weight adiponectin increase in Type 2 diabetes
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: High-molecular-weight/total adiponectin ratio increase in Type 2 diabetes
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Total adiponectin increase in Type 1 diabetes
Number of subjects: 136
Study: 27770695

Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 176
Study: 27770774

Group type: EXPERIMENTAL
Intervention: Combined surgery including pseudarthrosis resection, intramedullary rodding, autogenous iliac bone grafting and Ilizarov's fixator.
Number of subjects: 56
Study: 27771496

Group type: EXPERIMENTAL
Intervention: Y-90 ibritumomab-tiuxetan as part of reduced-intensity conditioning (RIC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab 250 mg (days -21 and -14)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fludarabine 30 mg/m2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27771544

Group type: EXPERIMENTAL
Intervention: Nilotinib 400mg twice daily for 24 months
Number of subjects: 45
Study: 27771610

Group type: EXPERIMENTAL
Intervention: Tivozanib (1.5 mg daily, 3 weeks on 1 week off, 28-day cycle)
Number of subjects: 58
Study: 27773811

Group type: EXPERIMENTAL
Intervention: Transcervical resection of adhesions (TCRA) and endometrial biopsy
Number of subjects: 82
Study: 27774033

Group type: EXPERIMENTAL
Intervention: Inhaled capsaicin solution challenge
Number of subjects: 4

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 4
Study: 27774059

Group type: EXPERIMENTAL
Intervention: Music Upper Limb Therapy-Integrated (MULT-I), 45-min intervention, twice a week for 6 weeks
Number of subjects: 13
Study: 27774495

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA treatments
Number of subjects: 1038

Group type: COMPARATOR
Intervention: Cervical dystonia
Number of subjects: 1038
Study: 27774730

Group type: EXPERIMENTAL
Intervention: In-center daily hemodialysis (6 days/week)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Nocturnal home hemodialysis (6 nights/week)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Conventional thrice weekly hemodialysis
Number of subjects: 237
Study: 27774758

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (Absorb BVS) implantation
Number of subjects: 500
Study: 27775823

Group type: EXPERIMENTAL
Intervention: CALM-CBT (Cognitive Behavioral Therapy)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: CALM-CBT
Number of subjects: 227

Group type: COMPARATOR
Intervention: CBT plus medication management
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Higher CBT dose
Number of subjects: 227

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 227
Study: 27776521

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL) administered under direct observation with a fat intake consisting of ready-to-use therapeutic food (RUTF - Plumpy'Nut®), twice daily during 3 days.
Number of subjects: 399
Study: 27776526

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 2351

Group type: EXPERIMENTAL
Intervention: High blood pressure component of MetS
Number of subjects: 2351

Group type: EXPERIMENTAL
Intervention: High density lipoprotein cholesterol (HDL)
Number of subjects: 2351

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 2351
Study: 27777218

Group type: EXPERIMENTAL
Intervention: Multimedia version of Taipei II developmental screening tool
Number of subjects: 390

Group type: COMPARATOR
Intervention: Paper-based version of Taipei II developmental screening tool
Number of subjects: 390
Study: 27777269

Group type: EXPERIMENTAL
Intervention: Surgical intervention with placebo control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 0
Study: 27777278

Group type: EXPERIMENTAL
Intervention: Prehospital EMS-initiated CPR
Number of subjects: 12877

Group type: EXPERIMENTAL
Intervention: Bystander-initiated CPR
Number of subjects: 12877
Study: 27777294

Group type: EXPERIMENTAL
Intervention: Ring annuloplasty with consideration of left ventricular (LV) size
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Larger LV end-systolic dimension (LVESd)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: LVESd/ring size ratio
Number of subjects: 214
Study: 27777594

Group type: EXPERIMENTAL
Intervention: Birch pollen exposure
Number of subjects: 38
Study: 27777606

Group type: EXPERIMENTAL
Intervention: Diet Rite Cola™ (18 mg sucralose, 18 mg acesulfame-potassium, 57 mg aspartame)
Number of subjects: 61

Group type: COMPARATOR
Intervention: NNS in water (0 mg, 68 mg, 170 mg, 250 mg sucralose)
Number of subjects: 61

Group type: COMPARATOR
Intervention: NNS in water
Number of subjects: 61
Study: 27777612

Group type: EXPERIMENTAL
Intervention: Evidence-based treatment of panic disorder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 27777873

Group type: EXPERIMENTAL
Intervention: 5% mannitol
Number of subjects: 52

Group type: COMPARATOR
Intervention: 0.9% sodium chloride
Number of subjects: 52
Study: 27778193

Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SXB) 9 g/night
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SXB) (all doses)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 27778639

Group type: EXPERIMENTAL
Intervention: Droxidopa (300 mg, 3 times a day)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Treatment-naive conditions
Number of subjects: 1
Study: 27779248

Group type: EXPERIMENTAL
Intervention: Intravenous busulfan (Bu)
Number of subjects: 76